Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 5 minute read Pharma Industry News Viking Therapeutics’ GLP-1/GIP dual agonist VK2735 impresses at ObesityWeek 2025 with sustained weight-loss efficacy Find out how Viking Therapeutics’ VK2735 is redefining obesity treatment with sustained clinical results — see what this breakthrough means for patients and investors today! bySoujanya RaviNovember 6, 2025